• Monash IVF Group delivered 11.6% revenue growth and 10.7% Underlying EBITDA growth in 1H25
• Underlying NPAT increased 5.5% to $15.8m, in line with guidance
• All three businesses - Domestic ARS, Women's Imaging and International ARS - delivered solid growth

Monash IVF Group (ASX: MVF) has announced its results for the six months ended 31 December 2024, delivering 11.6% revenue growth to $140.3m and 10.7% Underlying EBITDA growth to $35.6m. The company's Underlying NPAT increased 5.5% to $15.8m, in line with guidance. All three of Monash IVF's businesses - Domestic ARS, Women's Imaging and International ARS - contributed to the solid revenue and earnings growth. The company's market-leading success rates increased by 1.2% to 40.2%, and its domestic Stimulated Cycles market share grew by 0.6% to 21.5%. Monash IVF also continued to expand its operations, with 10 new domestic fertility specialists joining the company and the completion of a major infrastructure transformation, including a new Brisbane clinic scheduled for 1H26. The company's international operations also performed well, with KL Fertility delivering 12.2% stimulated cycles growth and the Singapore business moving to a new, larger clinic. Despite some short-term industry volatility, Monash IVF remains confident in the long-term demand drivers for IVF services, with the Australian industry stimulated cycles 21% above pre-COVID levels in 1H25.

FY2025 Underlying Group NPAT is expected to be between $30.0m and $31.0m, compared to $29.9m in the prior comparative period.

Monash IVF expects the Australian Assisted Reproductive Technology sector and the company's operations to continue benefiting from evolving underlying structural demand drivers, particularly from emerging services such as genetics, donor and egg freezing. The company also expects advanced maternal age and growing patient segments such as the LGBTQIA+ community to drive growth in the ART sector in the medium to long term.